{"id":29546,"date":"2024-06-25T14:55:44","date_gmt":"2024-06-25T13:55:44","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=29546"},"modified":"2024-06-25T14:55:44","modified_gmt":"2024-06-25T13:55:44","slug":"oms-rapport-amr-pipeline","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/","title":{"rendered":"OMS : Rapport AMR Pipeline"},"content":{"rendered":"\n<p>Depuis 2017, 16 nouveaux antimicrobiens ont <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-black-color\">re\u00e7us une autorisation d&#8217;une mise sur le march\u00e9 et 3 seraient sortis du march\u00e9.<\/mark><\/p>\n\n\n\n<p>Le rapport <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-black-color\">de l&#8217;OMS<\/mark> indique que ces nouveaux antimicrobiens ne sont malheureusement pas suffisants pour contrer l&#8217;\u00e9mergence de r\u00e9sistances et que plus d&#8217;investissements dans ce domaine sont n\u00e9cessaires.<\/p>\n\n\n\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-black-color\">Voici un extrait d&#8217;informations de ces 16 antimicrobiens, approuv\u00e9s depuis 2017 :<\/mark><\/strong><\/p>\n\n\n\n<ul>\n<li>13 sont des agents antimicrobiens traditionnels, dont 10 appartiennent \u00e0 des classes d&#8217;antimicrobiens pour lesquels des m\u00e9canismes de r\u00e9sistance sont d\u00e9j\u00e0 apparus.<\/li>\n<\/ul>\n\n\n\n<ul>\n<li>9 sont des antimicrobiens \u00e0 spectre \u00e9largi (Gram positif et n\u00e9gatif).<\/li>\n<\/ul>\n\n\n\n<ul>\n<li>Peu des nouveaux antimicrobiens peuvent \u00eatres administr\u00e9s oralement, la majorit\u00e9 n\u00e9cessitent une administration intraveineuse, plus difficile \u00e0 administrer.<\/li>\n<\/ul>\n\n\n\n<ul>\n<li>Peu des nouveaux antimicrobiens ont une forme p\u00e9diatrique associ\u00e9e.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-black-color\">L&#8217;Organisation Mondiale de la sant\u00e9 relate qu&#8217;il y a actuellement 97 antimicrobiens en cours de d\u00e9veloppement :<\/mark><\/p>\n\n\n\n<ul>\n<li>57 sont des agents antimicrobiens traditionnels dont 19 pour traiter les formes r\u00e9sistantes de tuberculose.<\/li>\n<\/ul>\n\n\n\n<ul>\n<li>40 sont des agents microbiens non-traditionnels dont 13 phages ou enzymes issues de phages, 7 anticorps, 3 agissant sur la virulence des bact\u00e9ries, 2 agissant sur le syst\u00e8me immunitaire, et 1 agissant sur le microbiome.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p>Retrouver le rapport complet, <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-black-color\">via les liens ci-apr\u00e8s\u00a0:<\/mark><br><a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240094000\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.who.int\/publications\/i\/item\/9789240094000<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/iris.who.int\/bitstream\/handle\/10665\/376944\/9789240094000-eng.pdf?sequence=1\">https:\/\/iris.who.int\/bitstream\/handle\/10665\/376944\/9789240094000-eng.pdf?sequence=1<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/cdn.who.int\/media\/docs\/default-source\/gcp\/key-facts-who-2023-antibacterial-agents-pipeline.pdf?sfvrsn=c91b89b5_1\">https:\/\/cdn.who.int\/media\/docs\/default-source\/gcp\/key-facts-who-2023-antibacterial-agents-pipeline.pdf?sfvrsn=c91b89b5_1<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Depuis 2017, 16 nouveaux antimicrobiens ont re\u00e7us une autorisation d&#8217;une mise sur le march\u00e9 et 3 seraient sortis du march\u00e9. Le rapport de l&#8217;OMS indique que ces nouveaux antimicrobiens ne sont malheureusement pas suffisants pour contrer l&#8217;\u00e9mergence de r\u00e9sistances et que plus d&#8217;investissements dans ce domaine sont n\u00e9cessaires. Voici un extrait d&#8217;informations de ces 16 [&hellip;]<\/p>\n","protected":false},"author":280,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[6697,6698,6699,6655,6621,6696],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>OMS : Rapport AMR Pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OMS : Rapport AMR Pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-25T13:55:44+00:00\" \/>\n<meta name=\"author\" content=\"Kevin Gr\u00e9goire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kevin Gr\u00e9goire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/\"},\"author\":{\"name\":\"Kevin Gr\u00e9goire\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/3bec06f8a90e180a3ba8957cae88c700\"},\"headline\":\"OMS : Rapport AMR Pipeline\",\"datePublished\":\"2024-06-25T13:55:44+00:00\",\"dateModified\":\"2024-06-25T13:55:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/\"},\"wordCount\":226,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"keywords\":[\"AMR\",\"Antimicrobial Resistance\",\"Antimicrobiens\",\"OMS\",\"OneHealth\",\"Organisation Mondiale de la Sant\u00e9\"],\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/\",\"name\":\"OMS : Rapport AMR Pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"datePublished\":\"2024-06-25T13:55:44+00:00\",\"dateModified\":\"2024-06-25T13:55:44+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"OMS : Rapport AMR Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/3bec06f8a90e180a3ba8957cae88c700\",\"name\":\"Kevin Gr\u00e9goire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OMS : Rapport AMR Pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/","og_locale":"en_GB","og_type":"article","og_title":"OMS : Rapport AMR Pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2024-06-25T13:55:44+00:00","author":"Kevin Gr\u00e9goire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Kevin Gr\u00e9goire","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/"},"author":{"name":"Kevin Gr\u00e9goire","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/3bec06f8a90e180a3ba8957cae88c700"},"headline":"OMS : Rapport AMR Pipeline","datePublished":"2024-06-25T13:55:44+00:00","dateModified":"2024-06-25T13:55:44+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/"},"wordCount":226,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"keywords":["AMR","Antimicrobial Resistance","Antimicrobiens","OMS","OneHealth","Organisation Mondiale de la Sant\u00e9"],"articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/","name":"OMS : Rapport AMR Pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"datePublished":"2024-06-25T13:55:44+00:00","dateModified":"2024-06-25T13:55:44+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/oms-rapport-amr-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"OMS : Rapport AMR Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/3bec06f8a90e180a3ba8957cae88c700","name":"Kevin Gr\u00e9goire"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-18 10:08:10","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/29546"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/280"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=29546"}],"version-history":[{"count":4,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/29546\/revisions"}],"predecessor-version":[{"id":29571,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/29546\/revisions\/29571"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=29546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=29546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=29546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}